Kite Pharma is a development-stage biotechnology company designing and developing immune-based therapies to treat cancer indications. The Company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a chimeric antigen receptor (CAR)-based therapy that is in Phase 2 clinical trials for patients with relapsed or refractory aggressive diffuse large B cell lymphoma, primary mediastinal B cell lymphoma, and transformed follicular lymphoma.

Type
Subsidiary
Parent Company
Gilead Sciences
HQ
Santa Monica, US
Founded
2009
Kite Pharma was founded in 2009 and is headquartered in Santa Monica, US
Report incorrect company information

Key People/Management at Kite Pharma

Arie Belldegrun

Arie Belldegrun

CEO
Rizwana Sproule

Rizwana Sproule

SVP
Brad Glover

Brad Glover

VP & Head of Strategy
William Go

William Go

VP of Clinical Development
Franck Auvray

Franck Auvray

VP, General Manager
Elizabeth Faust

Elizabeth Faust

VP Medical Affairs
Show more

Kite Pharma Office Locations

Kite Pharma has offices in Amsterdam, Hayes, Emeryville, El Segundo and in 1 other location
Santa Monica, US (HQ)
2400 Broadway
El Segundo, US
2355 Utah Ave
Emeryville, US
240 5858 Horton St
Amsterdam, NL
408 Science Park
Hayes, GB
Lakeside House Stockley Park 1 Furzeground Way
Show all (5)
Report incorrect company information

Kite Pharma Financials and Metrics

Summary Metrics

Founding Date

2009

Total Funding

$85.3 m

Investors

In total, Kite Pharma had raised $85.3 m. Kite Pharma is a subsidiary of Gilead Sciences

Kite Pharma Financials

Kite Pharma's revenue was reported to be $22.17 m in FY, 2016 which is a 28.5% increase from the previous period.
Annual
USDFY, 2015FY, 2016

Revenue

17.3 m22.2 m

Revenue growth, %

28%

General and administrative expense

44.2 m97.4 m

R&D expense

76.4 m197.9 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

5.1 m5.1 m4.8 m7.3 m9.8 m10.1 m

General and administrative expense

9.2 m9.8 m11.1 m16.5 m23.5 m25 m35.8 m41.1 m

R&D expense

9.3 m16.6 m21.7 m34.4 m47.4 m57.3 m65.9 m70.9 m

Operating expense total

18.4 m26.4 m32.9 m50.9 m70.9 m82.3 m101.7 m112 m
Annual
USDFY, 2014FY, 2015FY, 2016

Cash

392.8 m114.6 m

Inventories

286 k16.4 m13 m

Current Assets

631.1 m427.4 m

PP&E

30.1 m44.4 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

283.9 m263.2 m173 m199.6 m170.2 m128.8 m565.2 m147.8 m

Current Assets

435 m403.3 m381.5 m592.5 m541.6 m491.1 m819.2 m798.3 m

PP&E

4.3 m11.3 m20.3 m40.5 m42.5 m43.5 m46.2 m49.7 m

Goodwill

24.7 m25.8 m26.1 m26.4 m25.8 m26.1 m24.8 m26.6 m
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

(101.7 m)(267.1 m)

Depreciation and Amortization

4.6 m10.6 m

Inventories

1.3 m(14.8 m)3.3 m

Accounts Payable

2.3 m4.5 m2.3 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(15.1 m)(20.9 m)(27.4 m)(43.9 m)(64.3 m)(73.9 m)(90.4 m)

Accounts Payable

2.8 m1 m5.6 m4.5 m5.1 m9.6 m6.8 m11.3 m13.2 m
Show all financial metrics
Report incorrect company information

Kite Pharma News and Updates

Confirmed: Gilead to acquire Kite Pharma for $11.9bn

Shares in Kite Pharma, a US pharmaceuticals firm, have rocketed more than 16 per cent in pre-market trading after reports that it is being acquired. Gilead Sciences has confirmed it has offered $11.9bn (£9.2bn) for the company, in a deal first reported by the Wall Street Journal, $180 per share a…

Kite Pharma's ASCO ads aim to prep docs on CAR-T ahead of FDA approval

Drugmakers put up plenty of ads at ASCO, but only one campaign covered a class of meds that isn't even approved yet. That would be Kite Pharma's CAR-T cell therapy promos, designed to highlight the biotech's educational push for the immunotherapy.
Report incorrect company information